National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Teduglutide (Revestive®) is indicated for the treatment of patients aged 1 year and above with short bowel syndrome. Patients should be stable following a period of intestinal adaptation.

Rapid Review

Commenced Completed Outcome
13/03/2017 12/04/2017 Full Pharmacoeconomic Evaluation Recommended